"Weight-Loss Drug Shows Promise in Treating Liver Disease in MASH Patients"

Boehringer Ingelheim and Zealand Pharma's drug, survodutide, has shown success in a Phase 2 study for the treatment of the liver condition MASH, with 83% of patients experiencing significant improvements compared to those who received a placebo. The study met its primary endpoint of improvements in MASH without the worsening of fibrosis, and secondary endpoints, including an improvement in fibrosis, were also achieved. This development comes amid increasing competition in the obesity medicine field.